InveniAI, Kyowa Hakko Kirin Partner for Drug Discovery

InveniAI Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML), has entered a collaboration agreement with Kyowa Hakko Kirin to use AI and ML for drug discovery. 

Through this collaboration, Kyowa Hakko Kirin, a life sciences company with a focus on new biologics and medicines for unmet medical needs, will leverage InveniAI’s platform – AlphaMeld™ – to maximize portfolio value through the re-innovation of an existing therapeutic pipeline into new disease indications.

Mitsuo Satoh, Ph.D., executive officer, vice president, head, R&D Division of Kyowa Hakko Kirin said, "As we seek to fulfill our business vision to bring innovative treatments to patients faster, we very much expect that InveniAI’s platform, will not only enable us to identify alternate therapeutic value for our portfolio at an unprecedented speed, but also capitalize on our existing investment by reducing the time to market, clinical cost of development and enhancing the probability of clinical success."

Krishnan Nandabalan, Ph.D., chief executive officer and president of InveniAI said, "We are extremely pleased to initiate this collaboration to build on Kyowa Hakko Kirin’s clinically rich pipeline. AlphaMeld has industrialized the process of drug re-innovation by enabling the identification of complex associations between drugs/mechanisms and disease indications. The platform is patient-validated where multiple drug concepts have progressed through to human proof of clinical development."

Under the terms of the collaboration, InveniAI will receive an upfront payment as well as development milestones and commercialization payments.  Financial details are not disclosed.

-----------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.